AbCellera Biologics Inc. (ABCL) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Vancouver, BC, 캐나다. 현재 CEO는 Carl Hansen.
ABCL 을(를) 보유 IPO 날짜 2020-12-11, 596 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $1.14B.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
